PMID- 30199389
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200213
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 30
IP  - 4
DP  - 2019 Jun
TI  - Dopamine and serotonin antagonists fail to alter the discriminative stimulus 
      properties of +/-methylenedioxymethamphetamine.
PG  - 327-334
LID - 10.1097/FBP.0000000000000442 [doi]
AB  - Most studies on discriminative stimulus effects of 
      3,4-methylenedioxymethamphetamine (MDMA) have been conducted using a relatively 
      low dose (1.5 mg/kg), and those studies have invariably implicated serotonergic 
      mechanisms. In contrast, dopaminergic mechanisms mediate the discriminative 
      stimulus effects of amphetamine (AMPH). Some studies have suggested that the 
      discriminative stimulus effects of a higher (3.0 mg/kg) dose of MDMA might rely 
      on both serotonergic and dopaminergic mechanisms. This study aimed to determine 
      effects of selective dopamine (DA) and serotonin (5HT) antagonists on the 
      discriminative stimulus properties of AMPH (0.5 mg/kg) and MDMA (3.0 mg/kg). 
      Separate groups of rats were trained to discriminate AMPH (0.5 mg/kg) or MDMA 
      (3.0 mg/kg) from saline using a food-reinforced drug-discrimination procedure. 
      Effects of DA (SCH 23390: 0.003-0.03 mg/kg and eticlopride: 0.03-0.3 mg/kg) or 
      5HT (ritanserin: 1.0-10.0 mg/kg, WAY-100635: 0.3-1.0 mg/kg and GR129375: 
      1.0-3.0 mg/kg) antagonists on the discriminative stimulus effects of both drugs 
      were determined. Both DA antagonists dose-dependently decreased the AMPH but not 
      the MDMA discrimination. None of the 5HT antagonists altered the discriminative 
      stimulus effects of either drug. The MDMA (3.0 mg/kg) stimulus comprises both a 
      DAergic and 5HTergic response, and the results suggest that either one is 
      sufficient, but not required, to maintain the stimulus effects.
FAU - Schenk, Susan
AU  - Schenk S
AD  - School of Psychology, Victoria University of Wellington, Wellington, New Zealand.
FAU - Highgate, Quenten
AU  - Highgate Q
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Serotonin Antagonists)
RN  - 333DO1RDJY (Serotonin)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Amphetamine/metabolism/pharmacology
MH  - Animals
MH  - Discrimination Learning/*drug effects
MH  - Dopamine/physiology
MH  - Dopamine Antagonists/metabolism/pharmacology
MH  - Dopaminergic Neurons/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/metabolism/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonergic Neurons/*drug effects/physiology
MH  - Serotonin/physiology
MH  - Serotonin Antagonists/metabolism/pharmacology
EDAT- 2018/09/11 06:00
MHDA- 2020/02/14 06:00
CRDT- 2018/09/11 06:00
PHST- 2018/09/11 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2018/09/11 06:00 [entrez]
AID - 10.1097/FBP.0000000000000442 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2019 Jun;30(4):327-334. doi: 10.1097/FBP.0000000000000442.